This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Wang, Z. Articles by Sun, Y. PubMed PubMed Citation Articles by Wang, Z. Articles by Sun, Y.

Cardiac Glycosides Inhibit p53 Synthesis by a Mechanism Relieved by Src or MAPK Inhibition

¹ Division of Radiation and Cancer Biology, Department of Radiation Oncology and ² Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; ³ Department of Physiology and Pharmacology, University of Toledo, Toledo, Ohio; and ⁴ NIH Chemical Genomics Center, Bethesda, Maryland

Requests for reprints: Yi Sun, Department of Radiation Oncology, University of Michigan, 4424B Medical Science 1, 1301 Catherine Street, Ann Arbor, MI 48109. Phone: 734-615-1989; Fax: 734-763-1581; E-mail: sunyi{at}umich.edu.

Key Words: p53 • Src/MAPK signaling pathways • cardiac glycosides • Na⁺/K⁺ ATPase

p53 is regulated at multiple levels. We report here that p53, in multiple lines of human cancer cells, is down-regulated by cardiac glycoside drugs digoxin and ouabain, potent inhibitors of Na⁺/K⁺-ATPase. These drugs reduced the basal levels of p53 protein at nanomolar concentrations in a dose-, time-, and cancer cell line–dependent manner, but independent of p53 status of wild-type or mutant. The drugs also reduced the levels of p53 induced by its activators as well as p53 transfected into human cancer cells, regardless of its status. Interestingly, the drugs had no effect on endogenous p53 in two immortalized human cell lines. Mechanistically, p53 reduction occurred not at the mRNA levels but at the protein levels, as a result of reduced protein synthesis rather than enhanced degradation. The cellular sensitivity to drug-induced p53 reduction was not associated with the levels of subunits of Na⁺/K⁺-ATPase in different cell lines. Although lowering extracellular K⁺ did not reduce p53 as did ouabain and digoxin, it did potentiate both digoxin- and ouabain-induced p53 reduction in sensitive lines. Finally, p53 reduction seems to be triggered by activation of Src/mitogen-activated protein kinase (MAPK) signaling pathways upon drug binding to the Na⁺/K⁺-ATPase and can be completely blocked by the inhibitors of Src or MAP/ERK kinase. This is the first report that cardiac glycoside drugs, by initiating the Src/MAPK signaling pathways, reduce the p53 levels via inhibition of p53 protein synthesis. The drugs may be useful in the treatment of human cancers with a gain-of-function p53 mutation. [Cancer Res 2009;69(16):6556–64]